4.0 Review

Status of long-acting-growth hormone preparations-2015

期刊

GROWTH HORMONE & IGF RESEARCH
卷 25, 期 5, 页码 201-206

出版社

CHURCHILL LIVINGSTONE
DOI: 10.1016/j.ghir.2015.07.004

关键词

Growth hormone; Growth hormone deficiency; Growth hormone treatment; Long-acting growth hormone preparations

资金

  1. OPKO
  2. Novartis
  3. Novo Nordisk

向作者/读者索取更多资源

Growth hormone (GH) treatment has been an established therapy for GH deficiency (GHD) in children and adults for more than three decades. Numerous studies have shown that GH treatment improves height, body composition, bone density, cardiovascular risk factors, physical fitness and quality of life and that the treatment has few side effects. Initially GH was given as intramuscular injections three times per week, but daily subcutaneous injections were shown to be more effective and less inconvenient and the daily administration has been used since its introduction in the 1980s. However, despite ongoing improvements in injection device design, daily subcutaneous injections remain inconvenient, painful and distressing for many patients, leading to noncompliance, reduced efficacy and increased health care costs. To address these issues a variety of long-acting formulations of GH have been developed. In this review we present the current status of long-acting GH preparations and discuss the specific issues related to their development. (C) 2015 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.0
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据